Results 141 to 150 of about 1,124,617 (208)

First-line treatment with polatuzumab vedotin improves efficacy and survival in newly diagnosed patients with advanced diffuse large B-cell lymphoma: a multicentre retrospective analysis. [PDF]

Ann Med
Bai SJ, Shen XL, Tian WW, Liu ZY, Lang JY, Gao YN, Zhang CX, Wang YR, Geng Y, Shi YX, Liu Q, He JX.   +11 more
europepmc   +1 more source

Structural characterization of atrial natriuretic peptide amyloid fibrils from patients with atrial fibrillation. [PDF]

Nat Commun
Broggini L, Piccoli M, Chaves-Sanjuan A, Bonnet DMV, Cirillo F, Visentin C, Sonzini F, Signorelli P, Lavota I, Milazzo M, Nonnis S, Menicanti L, Ciconte G, Pappone C, Anastasia L, Ricagno S.   +15 more
europepmc   +1 more source

Comparative analysis of enamel mineral content and surface morphology alterations after bleaching: a study using colorimetric spectrophotometry and scanning electron microscopy. [PDF]

Front Dent Med
Kuruba A, Bolbandi GI, Desai SR, Indi S, Mustafa M, Alshehri AM, Alqahtani AR, Alanazi KK, Almuhaiza M, Alghannam S.   +9 more
europepmc   +1 more source

Antibody-Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives. [PDF]

Int J Mol Sci
Montalbano MC, Micillo M, Deaglio S, Vaisitti T.   +3 more
europepmc   +1 more source

Mechanical and mineralogical performance of sustainable cement composites with calcined palm oil leaf and calcined pine leaf Ash as supplementary cementitious materials. [PDF]

Sci Rep
Samadi M, Murali G, Wong LS, Din NM, Abdulkadir I, Abdellatief M, Abdul Shukor Lim NH, Mebrate Z.   +7 more
europepmc   +1 more source

Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. [PDF]

Front Oncol
Oura M, Toho M, Ikeda D, Fukuda N, Torres AS, Fujii F, Sakuma H, Uehara A, Tabata R, Narita K, Takeuchi M, Matsue K.   +11 more
europepmc   +1 more source

Enhancing TB case detection: a case study of Kenya's Global Fund-supported public-private mix. [PDF]

Public Health Action
Pola R, Mugambi-Nyaboga LN, Mwirigi N, Otieno A, Kathure I, Mukiri N, Kipkelwon S, Maina A, Warugongo P, Okoth C, Mwamsidu C, Kiptai T, Munene A, Mungai J, Chakaya J, Wandwalo E, Yassin MA, Ulo B.   +17 more
europepmc   +1 more source

Określanie pola

, 2021
openaire   +1 more source

Rozległe pola

, 2018
openaire   +2 more sources

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. [PDF]

J Clin Oncol
Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Leão Cordeiro de Farias D, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J.   +27 more
europepmc   +1 more source